Lymphoma / Leukemia Program Clinical Trials
The following is a list of clinical trials with which this cancer care program is currently involved. Talk to your doctor to find out if a clinical trial is right for you.
Hodgkins Lymphoma Clinical Trials
A Phase I Dose Escalation Study of Hydroxyurea in Combination with SCH900776 in Advanced Malignant Solid Tumors
Hodgkins Lymphoma
D1049
McGowan
A Phase II Trial of Response-Adapted Therapy of Stage III-IV Hodgkin Lymphoma Using Early Interim FDG-PET Imaging
Hodgkins Lymphoma
S0816
Lansigan
An Open-Label, Randomized, Phase 3 Study Of Inotuzumab Ozogamicin Administered In Combination With Rituximab Compared To Defined Investigator's Choice Therapy In Subjects With Relapsed Or Refractory CD22-Positive Aggressive Non-Hodgkin Lymphoma Who Are Not Candidates For Intensive High-Dose Chemotherapy
Hodgkins Lymphoma
F11077
Lansigan
Early vs. Later Palliative Cancer Care: Clinical and Biobehavioral Effects
Hodgkins Lymphoma
D0946
Bakitas
Phase II Trial of Response-Adapted Chemotherapy Based on Positron Emission Tomography for Non-Bulky Stage I and II Hodgkin Lymphoma
Hodgkins Lymphoma
C50604
Bengtson
Phase II Trial of Response-Adapted Therapy Based on Positron Emission Tomography (PET) for Bulky Stage I and Stage II Classical Hodgkin Lymphoma (HL)
Hodgkins Lymphoma
C50801
Bengtson
Leukemia, Other Clinical Trials
A Phase 3, Randomized, Controlled, Double-Blind, Multinational Clinical Study of the Efficacy and Safety of Vosaroxin and Cytarabine Versus Placebo and Cytarabine in Patients With First Relapsed or Refractory Acute Myeloid Leukemia (VALOR)
Leukemia, Other
F11030
Gautier
A Phase II Study of Dasatinib (Sprycel) (IND # 73969, NSC # 732517)as Primary Therapy Followed by Transplantation for Adults >=50 years with Newly Diagnosed Ph+ Acute Lymphoblastic Leukemia by CALGB, ECOG, SWOG, and NCIC CTG
Leukemia, Other
C10701
Rauwerdink
A Phase III Randomized Study of Oral Sapacitabine in Elderly Patients with Newly Diagnosed Acute Myeloid Leukemia
Leukemia, Other
F11057
Gautier
A Phase III Study of Risk Directed Therapy for Infants with Acute Lymphoblastic Leukemia (ALL): Randomization of Highest Risk Infants to Intensive Chemotherapy +/- FLT3 Inhibition
Leukemia, Other
AALL0631
Chaffee
A Randomized, Double-blind, Placebo-controlled, Multi-center Phase III Study of RAD001 Adjuvant Therapy in Poor Risk Patients With Diffuse Large B-Cell Lymphoma (DLBCL) of RAD001 Versus Matching Placebo After Patients Have Achieved Complete Response With First-line Rituximab-chemotherapy
Leukemia, Other
F1037
Lansigan
An Intergroup Phase II Clinical Trial for Adolescents and Young Adults with Untreated Acute Lymphoblastic Leukemia (ALL)
Leukemia, Other
C10403
Hill
Classification of Newly Diagnosed Acute Lymphoblastic Leukemia
Leukemia, Other
AALL08B1
Chaffee
Early vs. Later Palliative Cancer Care: Clinical and Biobehavioral Effects
Leukemia, Other
D0946
Bakitas
Lipoprotein Lipase Expression in Chronic Lymphocytic Leukemia
Leukemia, Other
D11065
Lansigan
Phase II Study of Reduced-Intensity Allogeneic Stem Cell Transplant for High Risk Chronic Lymphocytic Leukemia (CLL)
Leukemia, Other
C100701
Lowrey
Phase II Study of the Addition of Azacitidine (IND #87574, NSC # 102816) to Reduced-Intensity Conditioning Allogeneic Transplantation for Myelodysplasia (MDS) and Older Patients with AML
Leukemia, Other
C100801
Rauwerdink
Leukemia, not otherwise specified Clinical Trials
Early vs. Later Palliative Cancer Care: Clinical and Biobehavioral Effects
Leukemia, not otherwise specified
D0946
Bakitas
Lymphoid Leukemia Clinical Trials
A Genetic Risk-Stratified, Randomized Phase II Study of Four Fludarabine/Antibody Combinations for Patients with Symptomatic, Previously Untreated Chronic Lymphocytic Leukemia
Lymphoid Leukemia
C10404
Danilov
A Study of the Effect of Vinca Alkaloids on JNK Phosphorylation Status in Patients with Chronic Lymphocytic Leukemia (CLL)
Lymphoid Leukemia
D11199
Danilov
Early vs. Later Palliative Cancer Care: Clinical and Biobehavioral Effects
Lymphoid Leukemia
D0946
Bakitas
Intensified Methotrexate, Nelarabine (Compound 506U78; IND #52611) and Augmented BFM Therapy for Children and Young Adults with Newly Diagnosed T-cell Acute Lymphoblastic Leukemia (ALL)or T-cell Lymphoblastic Lymphoma
Lymphoid Leukemia
AALL0434
Chaffee
Intensive Treatment for Intermediate-Risk Relapse of Childhood B-Precursor Acute Lymphoblastic Leukemia (ALL): A Randomized Trial of Vincristine Strategies
Lymphoid Leukemia
AALL0433
Chaffee
Protocol to Obtain Blood Samples for Chronic Lymphocytic Leukemia Research
Lymphoid Leukemia
D0905
Lowrey
Multiple Myeloma Clinical Trials
An Open-Label, Dose-Escalation, Phase 1/2 Study of the Oral Form of MLN9708, a Next-Generation Proteasome Inhibitor, Administered in Combination With a Standard Care Regimen of Melphalan and Prednisone in Patients With Newly Diagnosed Multiple Myeloma Requiring Systemic Treatment (Sponsor Protocol #C16006)
Multiple Myeloma
F11196
Meehan
Early vs. Later Palliative Cancer Care: Clinical and Biobehavioral Effects
Multiple Myeloma
D0946
Bakitas
Evaluation of Immune Parameters and Function in Multiple Myeloma Patients and Healthy Individuals Blood and Marrow Samples
Multiple Myeloma
D1029
Meehan
Mycosis Fungoides Clinical Trials
Early vs. Later Palliative Cancer Care: Clinical and Biobehavioral Effects
Mycosis Fungoides
D0946
Bakitas
Myeloid and Monocytic Leukemia Clinical Trials
Early vs. Later Palliative Cancer Care: Clinical and Biobehavioral Effects
Myeloid and Monocytic Leukemia
D0946
Bakitas
Non-Hodgkins Lymphoma Clinical Trials
A Multicenter, Open Label, Phase II Study of Bendamustine and Rituximab followed by 90-yttrium (Y) Ibritumomab Tiuxetan for Untreated Follicular Lymphoma (Fol-BRITe study)
Non-Hodgkins Lymphoma
D1015
Lansigan
A Phase I Dose Escalation Study of Hydroxyurea in Combination with SCH900776 in Advanced Malignant Solid Tumors
Non-Hodgkins Lymphoma
D1049
McGowan
Early vs. Later Palliative Cancer Care: Clinical and Biobehavioral Effects
Non-Hodgkins Lymphoma
D0946
Bakitas
Ofatumumab and Bortezomib for Patients With Low-grade B-cell Non-Hodgkin Lymphoma That Relapse After Rituximab
Non-Hodgkins Lymphoma
W11001
Lansigan
Outcomes of Patients with Newly Diagnosed Peripheral T-Cell Lymphoma Treated with Aggressive Chemotherapy
Non-Hodgkins Lymphoma
SNF11159
Lansigan
Prospective, Longitudinal, Multinational Registry of Patients With Newly Diagnosed Peripheral T-Cell Lymphoma
Non-Hodgkins Lymphoma
F1038
Lansigan
Other Hematopoietic Clinical Trials
A Phase 3, Multicenter, Randomized, Double-Blind, Placebo-Controlled, Parallel-Group Study to Compare the Efficacy and Safety of Lenalidomide (Revlimid®) versus Placebo in Subjects with Transfusion-Dependent Anemia due to IPSS Low or Intermediate-1 Risk Myelodysplastic Syndromes Without Deletion 5Q[31] and Unresponsive or Refractory to Erythropoiesis-Stimulating Agents
Other Hematopoietic
F0945
Gautier
Early vs. Later Palliative Cancer Care: Clinical and Biobehavioral Effects
Other Hematopoietic
D0946
Bakitas
Non-Myeloablative Chemotherapy Followed by HLA-Matched Related Allogeneic Stem Cell Transplantation for Hematologic Malignancies
Other Hematopoietic
D0345
Hill
